ArticleRedox biology2026
The 1 -Cys peroxiredoxin, PRDX-6, suppresses an NHR-49-dependent pro-survival response, including the Flavin monooxygenase, FMO-2, that protects against fungal and bacterial infection.
Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Fasting requires Peroxiredoxin 2 and Peroxiredoxin 6 to coordinate redox dependent mitochondrial and lipid remodelling in Caenorhabditis elegans.Redox biology · 2026Article
- Chelerythrine enhances anti-fungi immunity inFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Reactive oxygen species (ROS)-induced cell damage contributes to many diseases. However, ROS also contribute to cell signaling and immune defences. As ubiquitous thiol peroxidases, peroxiredoxins (Prdx) play integral roles in balancing ROS functions. High levels of Prdx6 are associated with increased metastasis and resistance to chemotherapy, rendering Prdx6 a therapeutic target for treatment of a broad range of cancers. However, Prdx6 has additional activities, in lipid signaling and selenocysteine metabolism, and it remains unclear how Prdx6's thiol peroxidase activity contributes to disease. Here we have investigated the role/s of Prdx6 in the nematode worm Caenorhabditis elegans. Consistent with a ROS-protective role for PRDX-6, prdx-6 mutant C. elegans exhibit elevated levels of lipid oxidation, more apoptotic corpses in their germline and are more susceptible to the toxicity of diethyl maleate. However, unexpectedly, prdx-6 mutant C. elegans are more resistant to other forms of oxidative stress, long-lived and resistant to infection with two opportunistic human pathogens; the gram-positive bacteria Staphylococcus aureus and the dimorphic yeast Candida albicans. Our data suggest these phenotypes are associated with increased activity of the NHR-49(PPARα/HNF4) transcriptional regulator and intestinal expression of the Flavin monooxygenase, FMO-2. FMO-2 has a conserved, pro-survival function and is up-regulated in response to various stresses, including peroxides and S. aureus infection. Here we reveal that fmo-2 expression is also increased as an NHR-49-dependent protective response to C. albicans. Consistent with increased NHR-49 activity, prdx-6 mutant animals also contain increased levels of mono-unsaturated fatty acids. Accordingly, we propose that elevated expression of fmo-2 and other NHR-49 up-regulated genes contribute to the increased arsenite resistance and innate immunity of prdx-6 mutant animals. These findings further illustrate the complex roles that ROS, PRDX and lipid oxidation can play in oxidative stress resistance, immunity and ageing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.